ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.

LIAN LianBio

0,319
0,00 (0,00%)
26 Avr 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
LianBio LIAN NASDAQ Certificat de dépôt
  Variation Action Variation Action% Cours Dernier Dernier échange
0,00 0,00% 0,319 02:00:00
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
0,319 0,319
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
11/3/202412:51EDGAR2Form 25 - Notification of the removal from listing and..
28/2/202413:00GLOBELianBio Announces Voluntarily Delisting from Nasdaq
20/2/202422:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/2/202413:04EDGAR2Form 8-K - Current report
13/2/202413:00GLOBELianBio Announces Completion of Strategic Review
08/1/202412:13EDGAR2Form 144 - Report of proposed sale of securities
29/12/202313:56EDGAR2Form 144 - Report of proposed sale of securities
26/12/202322:10EDGAR2Form 3 - Initial statement of beneficial ownership of..
26/12/202322:07EDGAR2Form 8-K - Current report
26/12/202320:40APSBiotech Finds Success Following Holiday Weekend
26/12/202308:00GLOBELianBio Enters into Agreement Assigning its Rights for..
20/12/202314:05EDGAR2Form 8-K - Current report
20/12/202314:00GLOBELianBio Announces Departure of Chief Financial Officer
19/12/202322:26EDGAR2Form 8-K - Current report
19/12/202322:05GLOBELianBio Announces Departure of Chief Executive Officer
06/12/202322:23EDGAR2Form 8-K - Current report
06/12/202322:05GLOBELianBio’s Board of Directors Unanimously Determines not to..
01/12/202322:16EDGAR2Form 8-K - Current report
01/12/202322:05GLOBELianBio Confirms Receipt of Unsolicited Proposal from..
13/11/202322:28EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/11/202322:17EDGAR2Form 8-K - Current report
13/11/202322:05GLOBELianBio Reports Third Quarter 2023 Financial Results and..
30/10/202321:16EDGAR2Form 8-K - Current report
30/10/202321:05GLOBELianBio Announces Topline Results from Phase 3 LIBRA Trial..
25/10/202322:05GLOBELianBio Announces Presentation of Data from Phase 2a Study..
24/10/202316:25APSBiotech Shares Soar Premarket
24/10/202315:22DJNLianBio Shares Soar Premarket on Strategic Review, End of..
24/10/202312:59GLOBELianBio Enters into Agreement with Bristol Myers Squibb for..
28/8/202322:05GLOBELianBio Announces Results from Phase 3 EXPLORER-CN Trial of..
14/8/202322:21EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
14/8/202322:11EDGAR2Form 8-K - Current report
14/8/202322:05GLOBELianBio Reports Second Quarter 2023 Financial Results and..
03/8/202322:05GLOBELianBio Announces First Patient Treated in Phase 1 Trial of..
26/7/202314:30GLOBELianBio Partner Tarsus Pharmaceuticals Announces U.S. FDA..
18/7/202314:00GLOBELianBio Partner NANOBIOTIX Enters into License Agreement..
17/7/202312:00GLOBELianBio Announces Phase 3 EXPLORER-CN Data Accepted for..
12/7/202314:00GLOBELianBio Announces Clinical Supply Agreement with AstraZeneca..
26/6/202314:00GLOBELianBio Announces Marketing Approval of CAMZYOS®..
08/6/202313:00GLOBELianBio Completes Enrollment in Pivotal Phase 3 LIBRA Trial..
08/6/202300:21DJNADRs End Mostly Lower, Oatly and LianBio Trade Actively
06/6/202322:05GLOBELianBio Announces Topline Results from Phase 2a Proof of..
01/6/202322:15GLOBELianBio to Participate in Upcoming Investor Conferences
11/5/202322:15GLOBELianBio Reports First Quarter 2023 Financial Results and..
11/5/202313:00GLOBELianBio Announces Marketing Approval of CAMZYOS®..

Dernières Valeurs Consultées

Delayed Upgrade Clock